ATE233249T1 - Verfahren zur herstellung von hiv protease inhibitoren - Google Patents

Verfahren zur herstellung von hiv protease inhibitoren

Info

Publication number
ATE233249T1
ATE233249T1 AT94923392T AT94923392T ATE233249T1 AT E233249 T1 ATE233249 T1 AT E233249T1 AT 94923392 T AT94923392 T AT 94923392T AT 94923392 T AT94923392 T AT 94923392T AT E233249 T1 ATE233249 T1 AT E233249T1
Authority
AT
Austria
Prior art keywords
hiv protease
protease inhibitors
producing hiv
intermediates
chem
Prior art date
Application number
AT94923392T
Other languages
English (en)
Inventor
David Askin
Paul Reider
Kai Rossen
Richard J Varsolona
Kenneth M Wells
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE233249T1 publication Critical patent/ATE233249T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94923392T 1993-07-16 1994-07-11 Verfahren zur herstellung von hiv protease inhibitoren ATE233249T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9262793A 1993-07-16 1993-07-16
PCT/US1994/007695 WO1995002583A1 (en) 1993-07-16 1994-07-11 Process for making hiv protease inhibitors

Publications (1)

Publication Number Publication Date
ATE233249T1 true ATE233249T1 (de) 2003-03-15

Family

ID=22234214

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94923392T ATE233249T1 (de) 1993-07-16 1994-07-11 Verfahren zur herstellung von hiv protease inhibitoren

Country Status (20)

Country Link
US (4) US5637711A (de)
EP (2) EP1310495A3 (de)
JP (1) JPH09500131A (de)
KR (2) KR100362800B1 (de)
CN (1) CN1046715C (de)
AT (1) ATE233249T1 (de)
AU (1) AU679770B2 (de)
CA (1) CA2167408C (de)
CZ (1) CZ13096A3 (de)
DE (1) DE69432176T2 (de)
ES (1) ES2191683T3 (de)
FI (1) FI960206A7 (de)
HU (1) HUT76789A (de)
IL (1) IL110255A (de)
NZ (1) NZ269400A (de)
RO (3) RO117175B1 (de)
RU (1) RU2134263C1 (de)
UA (1) UA45317C2 (de)
WO (1) WO1995002583A1 (de)
ZA (1) ZA945194B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE116640T1 (de) * 1992-03-13 1995-01-15 Bio Mega Boehringer Ingelheim Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
CN1046272C (zh) * 1993-11-22 1999-11-10 广荣化学工业株式会社 N-叔丁基-2-吡嗪羧基酰胺类的制造方法
US5792869A (en) * 1994-11-04 1998-08-11 Yamakawa Chemical Industry Co., Ltd Process for preparing optically active piperazine derivatives and Intermediates for preparation
EP1125930A1 (de) * 1995-05-23 2001-08-22 Lonza Ag Optisch aktive 2-Piperazincarbonsäurederivate und Verfahren zu ihrer Herstellung
ES2164187T3 (es) * 1995-05-23 2002-02-16 Lonza Ag Procedimiento para la preparacion de derivados de acidos 2-piperazina-carboxilicos opticamente activos.
CA2201218C (en) * 1996-04-23 2004-09-28 Rudolf Fuchs Process for the preparation of optically active piperazine-2-carboxylic acid derivatives
US5981759A (en) * 1997-06-20 1999-11-09 Merck & Co., Inc. Process for indinavir intermediate
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
ES2295068T3 (es) 1999-11-24 2008-04-16 MERCK & CO., INC. Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097490A (en) * 1975-09-25 1978-06-27 Merck & Co., Inc. Pyroglutamic acid salts of t-butylamino-2,3-dihydroxypropane
SU1273359A1 (ru) * 1985-06-19 1986-11-30 Институт Хлорорганического Синтеза Ан Азсср 1-Пиперидино-4-(1-метил-2,2-гем.дихлорциклопропил)-2,3-эпоксибутан в качестве противозадирной и противоизносной присадки к смазочным маслам
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
US5075337A (en) * 1989-07-26 1991-12-24 G. D. Searle & Co. Alpha-deuterated 2-alkylaminoacetamide derivatives having reduced toxicity for treatment of CNS disorders
US5218114A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
CA2072237A1 (en) * 1991-07-02 1993-01-03 Merck & Co., Inc. Stereoselective production of hydroxyamide compounds from chiral –-amino epoxides
US5169952A (en) * 1991-07-02 1992-12-08 Merck & Co., Inc. Stereoselective production of hydroxyamide compounds from chiral α-amino epoxides
DK0541168T3 (da) * 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CZ293953B6 (cs) * 1993-07-16 2004-08-18 Mercká@Áco@Źáinc Způsob výroby meziproduktů pro výrobu inhibitorů HIV@proteázy a příslušné meziprodukty
US5463067A (en) * 1993-07-16 1995-10-31 Merck & Co., Inc. Process for making HIV protease inhibitors
US5461154A (en) * 1994-02-02 1995-10-24 Eli Lilly And Company Intermediate and process for making
TW472047B (en) * 1994-02-04 2002-01-11 Merck & Co Inc Process for making HIV protease inhibitors

Also Published As

Publication number Publication date
DE69432176D1 (de) 2003-04-03
CA2167408C (en) 2003-09-16
AU679770B2 (en) 1997-07-10
RO117019B1 (ro) 2001-09-28
EP1310495A3 (de) 2003-05-21
FI960206L (fi) 1996-03-14
KR960703879A (ko) 1996-08-31
CA2167408A1 (en) 1995-01-26
HU9600078D0 (en) 1996-03-28
RO117175B1 (ro) 2001-11-30
WO1995002583A1 (en) 1995-01-26
JPH09500131A (ja) 1997-01-07
US5618939A (en) 1997-04-08
HUT76789A (en) 1997-11-28
IL110255A0 (en) 1994-10-21
KR100362800B1 (ko) 2002-11-29
FI960206A0 (fi) 1996-01-16
EP0708763B1 (de) 2003-02-26
CN1046715C (zh) 1999-11-24
RO117176B1 (ro) 2001-11-30
ES2191683T3 (es) 2003-09-16
ZA945194B (en) 1995-02-15
US5693803A (en) 1997-12-02
KR100325279B1 (ko) 2002-07-22
EP1310495A2 (de) 2003-05-14
FI960206A7 (fi) 1996-03-14
DE69432176T2 (de) 2003-11-27
AU7326794A (en) 1995-02-13
RU2134263C1 (ru) 1999-08-10
CN1130905A (zh) 1996-09-11
NZ269400A (en) 1997-11-24
UA45317C2 (uk) 2002-04-15
IL110255A (en) 1998-12-06
CZ13096A3 (en) 1996-06-12
US5637711A (en) 1997-06-10
EP0708763A1 (de) 1996-05-01
EP1310495A9 (de) 2003-07-23
US5861512A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
NO303574B1 (no) Ny fremgangsmÕte for fremstilling av 9-amino-6-demetyl-6-deoksytetracykliner
NO983099D0 (no) Nye retrovirale proteasehemmere
ATE155779T1 (de) Retrovirale protease-inhibitoren
DE69432176D1 (de) Verfahren zur herstellung von hiv protease inhibitoren
DK0503453T3 (da) Fremgangsmåde til fremstilling af cephalosporiner og mellemprodukter i denne fremgangsmåde
ATE171164T1 (de) Verfahren zur herstellung von heterocyclischen tertiäraminen
ES2113975T3 (es) Azida de tri-alquil superior-estaño y su uso.
DE69426979D1 (de) Verfahren zur herstellung von hiv-proteasehemmern
ATE210662T1 (de) Verfahren zur herstellung von epoxiden
DK0782996T3 (da) Fremgangsmåde til fremstilling af N-biphenylmethylthiadiazolinderivat eller salt deraf og mellemprodukt til fremstilling af
NO178231C (no) Umettede polyesterharpiksblandinger og anvendelse av disse
ATE385232T1 (de) Verfahren zur herstellung von 3, 3', 6, 6'- tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'- tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
DK0662475T3 (da) Fremgangsmåde til fremstilling af 2-perfluoralkyl-3-oxazolin-5-on.
DE69819504D1 (de) Verfahren zur herstellung von 2-alkylthiobenzonitril-derivaten
ATE159519T1 (de) Verfahren zur herstellung von n-phenyl-n-(4- piperidinyl)amid-derivaten
EP0670305A4 (de) Verfahren zur herstellung von 3-amino-2-hydroxy-1-propanol-derivaten.
DK0675880T3 (da) Quinolondisulfider som mellemprodukter
ATE330946T1 (de) Verfahren zur herstellung einer benzylamin- verbindung
FI944967L (fi) Menetelmiä proteolyyttisen entsyymin inhibiittoreina käyttökelpoisten sakkariinijohdannaisten ja niiden välituotteiden valmistamiseksi
FI863897L (fi) Kemiskt foerfarande.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties